As the Indian Pharmaceutical Market (IPM) continues its upward trajectory, Augmentin by GlaxoSmithKline (GSK) has stood the ...

New Delhi: GlaxoSmithKline's antibiotic drug Augmentin has risen to the top slot in the Indian pharmaceutical market, pushing the popular anti-diabetes drug Glycomet GP to the second slot.

GlaxoSmithKline Pharmaceuticals on Tuesday reported a 16 per cent year-on-year increase in its consolidated net profit to Rs 252 crore in the September quarter, aided by robust sales across segments.